Almost ten years ago, aberrant activation of the KRAS pathway was shown to promote glucose avidity in pancreatic tumors, whereby KRAS mutations were associated with the upregulation of the glucose transporter GLUT1, and enzymes that execute aerobic glycolysis, such as LDHA [13,37]. The gene discussed is SLC2A1; the disease is pancreatic neoplasm.